IonQ, Rigetti Computing, D-Wave Quantum, and Quantum Computing Inc. Are Sending Shockwaves Through Wall Street With This $895 Million Warning

Quantum pure-play stocks have surged roughly 400% to 1,820% over two years, but insiders at IonQ, Rigetti, D-Wave and Quantum Computing Inc. collectively sold a net $895.1 million of stock since Sept. 18, 2024 while making only $2.26 million of purchases. Valuations appear highly stretched, with trailing P/S ratios of 55.7x for IonQ, 391.2x for Rigetti, 494.1x for D-Wave and 183.3x for Quantum Computing. The article argues that limited commercialization, historically unsustainable valuations and the risk of an early-stage technology bubble make the group vulnerable to a sharp correction.

Analysis

The relevant signal is not insider selling in isolation; it is the asymmetry between speculative valuation, cash burn, and a financing-dependent business model. For RGTI, QBTS, and QUBT in particular, a repricing need not await a technology failure: a routine quarterly revenue miss, higher R&D spend, or an at-the-market issuance can reset the equity narrative because their valuation support is primarily duration and retail momentum rather than near-term free cash flow. The second-order beneficiary is incumbent compute infrastructure—NVDA, IBM, and cloud platforms—where quantum optionality is embedded in businesses supported by existing demand and balance sheets.

Over the next days, this article alone is unlikely to break momentum; it is a widely understood valuation critique and sentiment can remain reflexive. The 1-3 month catalyst window is earnings and financing disclosures: backlog conversion, bookings quality, gross-margin progression, cash runway, and dilution are more decision-useful than partnership announcements. Over 6-18 months, the key divide will be whether error-correction progress produces repeatable commercial workloads; absent that, the sector faces multiple compression toward a venture-style option value rather than a software-like revenue multiple.

Contrarianly, a blanket short across the group is dangerous. Quantum names can rally sharply on government awards, hyperscaler distribution deals, technical milestones, or a broader AI-capex risk-on tape, while constrained float and retail ownership can make borrow costly. IONQ is the relative quality hedge within the basket: if quantum enthusiasm persists, it is more likely to attract institutional flows, making RGTI/QBTS/QUBT cleaner relative shorts—but this must be validated against cash runway, short interest, and borrow before sizing.

Key Decisions for Investors

• Establish a 3-6 month relative-value basket: long IONQ versus equal-dollar short RGTI, QBTS, and QUBT. The thesis is dispersion rather than a sector call: capital should consolidate into the perceived platform leader if risk appetite remains intact, while smaller peers remain more exposed to financing and execution shocks. Exit if the short basket outperforms IONQ by 25% from entry or if verified commercial bookings materially accelerate across the smaller names.
• For outright downside exposure, prefer defined-risk IONQ put spreads 3-6 months out rather than naked shorts; use strikes around 10-15% out-of-the-money for the long put and 30-40% out-of-the-money for the short put. Enter only after confirming liquid open interest and implied volatility below the post-earnings event premium; the intended catalyst is earnings guidance or a capital raise, not this commentary.
• Avoid new long exposure to RGTI, QBTS, and QUBT until filings establish at least 12 months of cash runway without material equity issuance and show backlog converting into recognized revenue. A financing announcement, going-concern language, or materially weaker gross-margin guidance would be a trigger to add to shorts, subject to borrow availability.
• Use NVDA or a diversified compute-infrastructure proxy as the higher-quality way to retain exposure to quantum-adjacent enthusiasm. This hedges the risk that quantum headlines lift the entire thematic complex while limiting dependence on commercialization timelines that remain difficult to underwrite.